Which is better, BPC-157 or TB-500?
The two are tied on the things that matter most: both are graded animal only for the injectable form, both have the same regulatory status (off Category 2, recommended by PCAC, not yet on the bulks list), and both are prohibited by WADA. BPC-157's animal data are more specific to tendon and gastrointestinal injury but come mostly from one research group; thymosin beta-4 has independent skin wound and cardiac studies and one human eye drop trial, but products sold as TB-500 may be a fragment rather than the full peptide. The honest answer is that no human evidence favors either, and the choice depends on which animal model is closer to the problem. [1] [2] [5] [7] [9] [10]
How do BPC-157 and TB-500 compare?
| Dimension | BPC-157 | TB-500 (thymosin beta-4) |
|---|---|---|
| What it is [4] [8] | Synthetic 15 amino acid fragment of a gastric protein (body protection compound). Not found as such in the body. | Synthetic version or fragment of thymosin beta-4, a 43 amino acid actin binding peptide present in nearly all human cells. Some products claim to be only the LKKTETQ fragment. |
| Proposed mechanism [1] [3] [6] [8] | Upregulates growth factor receptor signaling, modulates the nitric oxide system, and promotes angiogenesis through VEGFR2 in animal and cell models. | Sequesters G-actin to support cell migration, activates the ILK and Akt survival pathway, and reduces inflammation and scarring in animal and cell models. |
| Strongest animal evidence [1] [4] [5] [6] | Rat Achilles tendon transection: faster healing and more tendon fibroblast outgrowth, survival, and migration. Rodent gut studies report healing of NSAID ulcers, fistulas, and anastomoses. | Rat full thickness wounds: reepithelialization up 42% at day 4 and up to 61% at day 7. Mouse heart attack model: better cardiomyocyte survival and cardiac function. |
| Human evidence [2] [7] [13] [15] | No controlled human trial. Three small uncontrolled pilot reports from one clinic (knee pain, interstitial cystitis, and intravenous safety) reported benefit or no adverse events but had no comparison group. | No human trial of injected TB-500 products. One phase 2 trial of 0.1% thymosin beta-4 eye drops in 72 adults with dry eye missed both primary endpoints, and phase 1 intravenous studies of full length thymosin beta-4 in healthy volunteers found it well tolerated; neither tested injury healing. |
| Independence of the research base [2] [5] [6] | Most studies come from a small number of laboratories, mostly in Zagreb, with limited independent replication. | Wound and cardiac findings come from several independent groups, including a Nature paper on cardiac repair. |
| Routes in the literature [4] [5] [7] | Rodent work used intraperitoneal injection, oral dosing in drinking water, and topical application; BPC-157 is reported to be active orally in animals. | Rodent work used topical application and intraperitoneal injection; the only human use is topical eye drops. |
| FDA and compounding status [9] [10] | Removed from 503A Category 2 on April 15, 2026; PCAC recommended adding it to the 503A bulks list in July 2026; no final rule yet. Not FDA approved. | Removed from 503A Category 2 on April 15, 2026; PCAC recommended adding it to the 503A bulks list in July 2026; no final rule yet. Not FDA approved. |
| Note: Identical status today: neither is on the 503A bulks list, so a 503A pharmacy has no federal basis to compound either from bulk. | ||
| WADA status [11] [12] | Prohibited at all times under S0 (non-approved substances). | Prohibited at all times under S2; thymosin beta-4 and TB-500 are named on the list. |
| Typical cost [9] | No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price. | No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price. Often marketed alongside BPC-157, which has the same status. |
| Note: Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | BPC-157 | TB-500 (thymosin beta-4) |
|---|---|---|
| Class | Synthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compound | Synthetic version or fragment of thymosin beta-4, a 43 amino acid actin sequestering peptide present in nearly all human cells |
| What it is | A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a shifting FDA compounding status. | Copy or fragment of the repair protein thymosin beta-4: strong animal data, small human trials of the full protein, no trial of injected TB-500; WADA banned. |
| Evidence | Evidence: Animal-only evidence | Evidence: Animal-only evidence |
| FDA status | Regulatory: Under FDA review | Regulatory: Under FDA review |
| Compounding | Removed from the FDA 503A Category 2 list (substances with significant safety risks) on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding BPC-157 to the 503A bulks list. As of the last verification date FDA has not published a final rule listing it, so state boards and pharmacies vary in whether they will compound it. It is not an FDA approved drug and is not eligible for 503B outsourcing. | Removed from the FDA 503A Category 2 list (substances nominated for compounding that raise significant safety risks) on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding TB-500 to the 503A bulks list. As of the last verification date FDA has not published a final rule listing it, so it is not on the 503A bulks list and a 503A pharmacy has no federal basis to compound it from bulk; state boards cannot authorize what federal law does not. It is not an FDA approved drug and is not eligible for 503B outsourcing. Products sold as research chemicals are not lawful for human use. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Subcutaneous injection (as sold), Oral capsule (as sold), Intraperitoneal, oral in water, and topical (animal studies) | Subcutaneous or intramuscular injection (as sold), Topical eye drops (human dry eye trial, investigational), Topical to wound or intraperitoneal (animal studies) |
| Typical cost | No lawful compounded price: BPC-157 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | No lawful compounded price: TB-500 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Last verified |
Has BPC-157 been tested directly against TB-500?
No published trial has compared BPC-157 and TB-500 directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do BPC-157 and TB-500 cost?
| Dimension | BPC-157 | TB-500 (thymosin beta-4) |
|---|---|---|
| Typical cost | No lawful compounded price: BPC-157 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | No lawful compounded price: TB-500 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Price detail | BPC-157 price by channel | TB-500 (thymosin beta-4) price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Are BPC-157 and TB-500 combined?
BPC-157 and TB-500 are sold together in the premixed blends below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend pages cover what is in each product, the evidence for each ingredient, and legal status.
- GLOW: No lawful path.
- KLOW: No lawful path.
- Wolverine stack: Awaiting FDA final rule.
Frequently asked questions
Which is better for tendon injuries, BPC-157 or TB-500?
Neither has been tested in a published human trial for tendon injury. BPC-157 has the more tendon specific animal data (rat Achilles transection and tendon explant studies), while thymosin beta-4 data are mainly in skin wounds and heart tissue. Standard care for tendon injury remains load management and physical therapy. [1] [2] [5]
Is there any human evidence for TB-500?
Only indirectly. A phase 2 trial of 0.1% thymosin beta-4 eye drops in 72 adults with dry eye did not meet its primary endpoints, though some secondary endpoints improved, and a phase 1 intravenous study of full length thymosin beta-4 in healthy volunteers found it well tolerated. No human trial of injected TB-500 for any injury has been published. [7] [15]
Can a pharmacy legally compound BPC-157 and TB-500 now?
No, not from bulk today. Both were removed from FDA's 503A Category 2 list on April 15, 2026, and PCAC recommended both for the 503A bulks list in July 2026, but that recommendation is advisory. Until FDA publishes a final rule, neither is on the 503A bulks list, so a 503A pharmacy has no federal basis to compound them from bulk, and state boards cannot authorize what federal law does not. Neither is eligible for 503B outsourcing. [9] [10]
Are BPC-157 and TB-500 banned in sport?
Yes. BPC-157 is prohibited at all times under S0 (non-approved substances), and thymosin beta-4 and TB-500 are named under S2 of the WADA Prohibited List. [11] [12]
Is stacking BPC-157 and TB-500 supported by evidence?
No. No controlled study in animals or people has tested the two together, so claims of synergy are not supported by published data. The only published human report that used both was a retrospective knee pain survey in which 4 people received the pair, with no comparison group. Both share a theoretical concern about promoting existing tumors because they drive angiogenesis or cell migration in animal models. [2] [8] [14]
Conditions studied
From the blog
- BPC-157 before and after: reviews, results, and what controlled studies show
BPC-157 reviews and before and after stories are everywhere. Controlled results exist only in rats. What the animal healing timelines show, what the human pilots found, and why anecdotes mislead.
- BPC-157 human studies: every published report and registered clinical trial
Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
- Oral BPC-157: what capsules and pills were tested for, and what is missing
Oral BPC-157 worked in rat gut, ligament, and fistula studies. No study has measured how much an oral capsule absorbs in people, and the two registered oral studies have posted no results.
- TB-500 vs thymosin beta-4: is it the same peptide?
TB-500 is not the same molecule as thymosin beta-4. What each one is, which has human data, what is known about capsules and sprays, and what the evidence says about cancer.
- What is peptide therapy? What clinics sell, what is legal, and what works
Peptide therapy means three different things: FDA-approved drugs, compounded prescriptions, and research-only products. Here is how to tell them apart, what the evidence shows, and what it costs.
More on the blog
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011
- [2]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
- [3]Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (Curr Neuropharmacol 2016)PubMed 27138887, 2016
- [4]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
- [5]Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999PubMed 10469335, 1999
- [6]Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004PubMed 15565145, 2004
- [7]Sosne G et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial. Clin Ophthalmol 2015PubMed 26056426, 2015
- [8]Goldstein AL et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012PubMed 22074294, 2012
- [9]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [10]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 23). BPC-157 vs TB-500: evidence, cost, and legality. https://peptideagent.ai/compare/bpc-157-vs-tb-500- HTML link
<a href="https://peptideagent.ai/compare/bpc-157-vs-tb-500">BPC-157 vs TB-500: evidence, cost, and legality</a>, PeptideAgent, updated September 23, 2026.